These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27956102)

  • 1. Pharyngolaryngeal ulcers associated with the improper use of alendronate.
    Sakaida H; Yuasa H; Fukutome K; Takeuchi K
    Auris Nasus Larynx; 2017 Dec; 44(6):762-765. PubMed ID: 27956102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature.
    Hanna J; Bee J; Sataloff RT
    Ear Nose Throat J; 2012 Nov; 91(11):484-5. PubMed ID: 23288794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms and Upper Gastrointestinal Mucosal Injury Associated with Bisphosphonate Therapy.
    Yamamoto K; Kishino M; Nakamura S; Tokushige K
    Intern Med; 2019 Apr; 58(8):1049-1056. PubMed ID: 30626809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
    Kharazmi M; Persson U; Warfvinge G
    J Oral Maxillofac Surg; 2012 Dec; 70(12):2793-7. PubMed ID: 22609135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ulcers, a little known adverse effect of alendronate: review of the literature.
    Kharazmi M; Sjöqvist K; Warfvinge G
    J Oral Maxillofac Surg; 2012 Apr; 70(4):830-6. PubMed ID: 21816532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate-Mediated Oral Ulcers: A Rare Differential Diagnosis of Erosive Oral Lesions.
    Lengfeld J; Buder-Bakhaya K; Goebeler M; Wobser M
    Dermatology; 2016; 232(1):117-21. PubMed ID: 26458129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
    Schneider JP
    Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral mucosal irritation with incorrect use of alendronate.
    Aleid W; Sidebottom A
    Br J Oral Maxillofac Surg; 2009 Mar; 47(2):170-1. PubMed ID: 18814944
    [No Abstract]   [Full Text] [Related]  

  • 11. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
    Chiu WY; Lee JJ; Tsai KS
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: evaluation of absorption, safety, and effects after intrapulmonary administration in rats.
    Katsumi H; Takashima M; Sano J; Nishiyama K; Kitamura N; Sakane T; Hibi T; Yamamoto A
    J Pharm Sci; 2011 Sep; 100(9):3783-92. PubMed ID: 21567410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis.
    Terashima T; Hiramatsu K; Shimatani A; Matsuda M; Ogino H; Satomura Y; Noda Y
    Endoscopy; 2006; 38 Suppl 2():E37. PubMed ID: 17366400
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bisphosphonates for osteoporosis].
    Narusawa K; Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of esophageal ulcer caused by alendronate sodium tablets.
    Ueda K; Muto M; Chiba T
    Gastrointest Endosc; 2011 May; 73(5):1037-8. PubMed ID: 21521571
    [No Abstract]   [Full Text] [Related]  

  • 16. Bisphosphonate-related osteonecrosis of the palatal torus.
    Kaneko K; Takahashi H
    ORL J Otorhinolaryngol Relat Spec; 2014; 76(6):353-6. PubMed ID: 25613415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
    Miller PD; McCarthy EF
    Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral ulcer associated with alendronate: a case report.
    Kharazmi M; Sjöqvist K; Rizk M; Warfvinge G
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Dec; 110(6):e11-3. PubMed ID: 20674418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In brief: effervescent alendronate.
    Med Lett Drugs Ther; 2012 Oct; 54(1401):84. PubMed ID: 23059422
    [No Abstract]   [Full Text] [Related]  

  • 20. Osteochemonecrosis of jaws and bisphosphonates.
    Khosa AD; Nayyar MS; Beirne JC
    Ir Med J; 2007 Mar; 100(3):410-1. PubMed ID: 17491545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.